Sign in
NKTX Stock Price, Chart, Stats & News
Nkarta, Inc.
Save
Nkarta, Inc. (NKTX) does not currently pay a dividend.
199.61M
Market cap
–
Current P/E
–
Forward P/E
NKTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -25.75% |
ROE | -30.02% |
D/E | 0.24x |
Interest coverage ratio | – |
NKTX valuation
P/E | – |
P/S | – |
P/B | 0.49x |
P/CF | -1.72x |
P/FCF | -1.63x |
P/OCF | -1.72x |
PEG | 1.01x |
EV multiple | -1.08x |
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG.
Similar securities
Based on sector and market capitalization
Report issue